Moderna, Inc. (mrna)
MRNA Estimates
Public analyst price targets and consensus snapshot for Moderna, Inc.. Deeper estimate history and models are available in Vest Terminal.
| Last price | $182.11 |
| Analyst mean target | $119.56 |
| Analyst high target | $170.00 |
| Analyst low target | $45.00 |
| Upside vs mean target | -34.3% |
| Consensus recommendation | Hold |
| Number of analysts | 18 |
| Forward P/E | -40.75 |
Start Free — open MRNA in Vest Terminal
Access live data, filings, ownership, and analysis for Moderna, Inc..
Moderna, Inc. FAQ
What does Moderna, Inc. (MRNA) do?
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; laten…
What is MRNA's P/E ratio?
Moderna, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does MRNA pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRNA in?
Moderna, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is MRNA's market capitalization?
Approximate market cap: $72.70B.
What are the main risks for MRNA?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of MRNA?
Potential positives include positive free cash flow ($299.25m), moderate leverage (debt/equity 19.04).
Where can I get analyst estimates for MRNA?
Public analyst price targets and consensus for Moderna, Inc. are on the free /stocks/mrna/estimates page. Deeper estimate history and models are available in Vest Terminal.